Patents by Inventor Riccardo Giovannini

Riccardo Giovannini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210369723
    Abstract: The present invention relates to novel purines of general formula A processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: June 3, 2020
    Publication date: December 2, 2021
    Inventors: Riccardo GIOVANNINI, Dieter WIEDENMAYER
  • Patent number: 11166958
    Abstract: Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: November 9, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • Patent number: 11155539
    Abstract: Disclosed are 4-pyridinylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: October 26, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • Patent number: 11104670
    Abstract: Disclosed are 4-pyrimidin-5-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: August 31, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • Patent number: 11046706
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: June 29, 2021
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • Publication number: 20210130362
    Abstract: The present invention relates to compound III and its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.
    Type: Application
    Filed: January 11, 2021
    Publication date: May 6, 2021
    Inventors: Michael Steven SAND, Holger ROSENBROCK, Riccardo GIOVANNINI, Masashi ADACHI, Bodo BETZEMEIER, Tobias BRODMANN, Takayuki KAMATA, Yohei KAWABATA, Masanori ITO, Daniel MARCKART, Manabu NAKATANI, Ulrike WERTHMANN
  • Patent number: 10919898
    Abstract: The present invention relates to compound III and its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: February 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Steven Sand, Holger Rosenbrock, Riccardo Giovannini, Masashi Adachi, Bodo Betzemeier, Tobias Brodmann, Takayuki Kamata, Yohei Kawabata, Masanori Ito, Daniel Marckart, Manabu Nakatani, Ulrike Werthmann
  • Publication number: 20210032259
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: October 20, 2020
    Publication date: February 4, 2021
    Inventors: Christoph HOENKE, Barbara BERTANI, Marco FERRARA, Giacomo FOSSATI, Sara FRATTINI, Riccardo GIOVANNINI, Scott HOBSON
  • Patent number: 10875867
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: December 29, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christoph Hoenke, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Sara Frattini, Riccardo Giovannini, Scott Hobson
  • Patent number: 10849907
    Abstract: The present invention relates to imidazopyridines of formula A processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: December 1, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Georg Dahmann, Cornelia Dorner-Ciossek, Lothar Kussmaul, Roland Pfau, Dieter Wiedenmayer
  • Patent number: 10675268
    Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: June 9, 2020
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Riccardo Giovannini, Yunhai Cui, Henri Doods, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
  • Patent number: 10640486
    Abstract: The present invention relates to compounds of general formula (I), wherein D1 to D3, -A-, n, R1, R2, Y1, L and y2 are defined as in claim 1, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: May 5, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Sara Frattini, Remko Bakker, Riccardo Giovannini, Giacomo Fossati, Dieter Hamprecht, Iain Lingard, Alexander Pautsch, Bernd Wellenzohn
  • Publication number: 20200123141
    Abstract: Disclosed are 4-pyridinylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: October 16, 2019
    Publication date: April 23, 2020
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Cornelia DORNER-CIOSSEK, Roland PFAU, Dieter WIEDENMAYER
  • Publication number: 20200123140
    Abstract: Disclosed are 4-pyrimidin-5-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: October 16, 2019
    Publication date: April 23, 2020
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Cornelia DORNER-CIOSSEK, Roland PFAU, Dieter WIEDENMAYER
  • Publication number: 20200121691
    Abstract: Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: October 16, 2019
    Publication date: April 23, 2020
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Cornelia DORNER-CIOSSEK, Roland PFAU, Dieter WIEDENMAYER
  • Patent number: 10577336
    Abstract: The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: March 3, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rocco Mazzaferro, Marco Ferrara, Riccardo Giovannini, Iain Lingard, Klaus Rudolf
  • Publication number: 20200039991
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: October 14, 2019
    Publication date: February 6, 2020
    Inventors: Christoph HOENKE, Barbara BERTANI, Marco FERRARA, Giacomo FOSSATI, Sara FRATTINI, Riccardo GIOVANNINI, Scott HOBSON
  • Patent number: 10479794
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: November 19, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christoph Hoenke, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Sara Frattini, Riccardo Giovannini, Scott Hobson
  • Publication number: 20190300541
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Application
    Filed: December 27, 2018
    Publication date: October 3, 2019
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • Publication number: 20190269650
    Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.
    Type: Application
    Filed: November 2, 2018
    Publication date: September 5, 2019
    Inventors: Riccardo Giovannini, Yunhai Cui, Henri Doods, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf